SciNeuro and Novartis sign global licensing deal for Alzheimer’s antibody
Under the deal, SciNeuro will receive $165m upfront and could earn up to $1.5bn in milestones.
Drug Development
Atara receives FDA complete response letter for Ebvallo BLA application
MediLink and Roche announce exclusive licensing agreement for YL201
Takeda and Halozyme sign global agreement for Enhanze technology
Santhera grants Agamree rights to Nxera for DMD
Octapharma receives FDA approval for new Fibryga formulation in AFD
Day One concludes Mersana Therapeutics acquisition
Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
